Pharmaceuticals, Biotechnology and Life Sciences
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–#AI— Systems Oncology, LLC (“SO”) and The Pritzker Organization, LLC (“TPO”) announced today that Pritzker Family Business Interests…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced…
NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces the clearance…
Bristol-Myers Squibb study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the…
Novartis has ended third quarter 2019 with reported net income of $2.0 billion, which as an 8% increase, driven by higher operating income and higher income from associated companies, saying in the press release Tuesday that its EPS was USD 0.90 (+11%, +14% cc), growing faster than net income driven by lower weighted average number of shares outstanding.
AstraZeneca on Monday said that that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer has met primary and secondary endpoints, showing that the addition of tucatinib was superior to trastuzumab and capecitabine alone, and the company is planning NDA Submission to U.S. FDA for first quarter of 2020.
Vertex Pharmaceuticals received FDA’s approval for Trikafta (elexacaftor/tezacaftor/ivacaftor), for treating cystic fibrosis in patients older than 12, who have at…
PARSIPPANY, N.J. & JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. and its affiliates today announced a settlement agreement with both Cuyahoga and…
CLEVELAND–(BUSINESS WIRE)–AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced this morning that they have agreed to…